PRESS RELEASES

Date Title and Summary View
Jun 25, 2018
Summary ToggleREMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call

BOSTON , June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, will host an investor conference call today, Monday, June 25 ,

Summary ToggleREMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
Jun 23, 2018
Summary ToggleZafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafgen presenting the Phase 2 clinical data and data from two supportive nonclinical studies at the

Summary ToggleZafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
Jun 7, 2018
Summary ToggleZafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors

Zafgen, Inc. also announces the retirements of Dr. Bruce Booth and Ms. Frances Heller from its Board of Directors BOSTON , June 07, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel

Summary ToggleZafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
May 30, 2018
Summary ToggleZafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer

BOSTON , May 30, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today the appointment of Brian McVeigh as Chief Business

Summary ToggleZafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer
May 8, 2018
Summary ToggleZafgen Reports First Quarter 2018 Operating and Financial Results

Multiple ZGN-1061 abstracts accepted for presentation at upcoming American Diabetes Association (ADA) Scientific Sessions ZGN-1061 Phase 1 SAD / MAD data published in Diabetes, Obesity and Metabolism BOSTON , May 08, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage

Summary ToggleZafgen Reports First Quarter 2018 Operating and Financial Results
May 2, 2018
Summary ToggleZafgen to Present at Deutsche Bank 43rd Annual Health Care Conference

BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield,

Summary ToggleZafgen to Present at Deutsche Bank 43rd Annual Health Care Conference
May 1, 2018
Summary ToggleZafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results

BOSTON , May 01, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a

Summary ToggleZafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results
Mar 7, 2018
Summary ToggleZafgen to Present at Cowen 38th Annual Health Care Conference
BOSTON , March 07, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey
Summary ToggleZafgen to Present at Cowen 38th Annual Health Care Conference
Mar 6, 2018
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
ZGN-1061 interim data suggest compound is safe and well-tolerated; no safety signals and placebo-like side effect profile ZGN-1061 interim efficacy data indicate significant A1C lowering vs. placebo at 8 weeks   ZGN-1258 for Prader-Willi syndrome (PWS) added to the pipeline; IND enabling studies
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
Mar 1, 2018
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results
BOSTON , March 01, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results